Pyridoxal 5'-phosphate binds specifically to soluble CD4 protein, the HIV-1 receptor. Implications for AIDS therapy.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Pyridoxal 5'-phosphate binds specifically to soluble CD4 protein, the HIV-1 receptor. Implications for AIDS therapy.

J Biol Chem. 1993 Apr 15;268(11):7643-5. Unique Identifier : AIDSLINE MED/93216724
Salhany JM; Schopfer LM; Veterans Administration Medical Center, Omaha, Nebraska.

Abstract: Considerable effort is being made to design anti-viral drugs for the human immunodeficiency virus type 1 (HIV-1) infection process. Some of this work has focused on CD4 protein, the HIV-1 receptor on T helper lymphocytes. One drug that binds to CD4 protein and inhibits both viral infection and growth is DIDS (4,4'-diisothiocyanato-2,2'-stilbenedisulfonate). DIDS is best known for its ability to inhibit erythrocyte band 3 anion exchange. Although the antiviral potency of DIDS is evident in vitro (IC50 approximately 30 microM), intravenous administration of DIDS should not be effective owing to the large number of band 3 molecules present on the red blood cell membrane (approximately 10(6)/cell), and to the very small Kd for DIDS binding to band 3 (approximately 30 nM). Therefore, we sought to identify other anion transport inhibitors that would bind weakly to band 3, but tightly to CD4 protein, and that could be administered to humans without significant toxic side effects. On the basis of our previous work with band 3 (Salhany, J. M., Rauenbuehler, P. B., and Sloan, R. L. (1987) J. Biol. Chem. 262, 15965-15973), we elected to study the binding of pyridoxal 5'-phosphate (PLP) to soluble CD4 protein. We have discovered that PLP binds surprisingly tightly to soluble CD4 protein (Kd = 45 microM), with a stoichiometry of about 1 mol of PLP/mol of protein. Furthermore, PLP binding was found to be competitive with DIDS for its binding site on soluble CD4 protein. These results suggest that PLP may be an effective anti-viral agent for the HIV-1 infection process.

Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Animal Antigens, CD4/GENETICS/ISOLATION & PURIF/*METABOLISM CHO Cells Hamsters Human HIV-1/*METABOLISM Kinetics Protein Binding Pyridoxal Phosphate/*METABOLISM Recombinant Proteins/ISOLATION & PURIF/METABOLISM Spectrometry, Fluorescence Spectrophotometry Support, U.S. Gov't, Non-P.H.S. SITS/*ANALOGS & DERIVATIVES/METABOLISM Transfection JOURNAL ARTICLE
930730
M9370739

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .